A first-in-human test of a dual-imaging coronary catheter is complete
Researchers at the University of California, Davis have completed a first-in-human study of a catheter-based imaging system intended to give clinicians a more detailed view of plaque inside coronary arteries. The device combines two optical techniques in one flexible catheter: fluorescence lifetime imaging, known as FLIm, and polarization-sensitive optical coherence tomography, or PS-OCT.
The work focuses on atherosclerosis, the buildup of plaque that narrows blood vessels and can contribute to heart attacks, strokes and other cardiovascular conditions. The UC Davis National Center for Interventional Biophotonic Technologies developed the system and received FDA approval this year to evaluate it as an investigational device in 10 patients. The team completed imaging of the final participant in August.
The study is an early clinical step, not evidence that the technology improves patient outcomes. But it establishes that a laboratory-developed system can be taken into a first-in-human catheter study and used to collect information from coronary arteries.
Two views of the same artery wall
Current assessments of coronary artery disease often rely on images that show the artery’s shape, degree of narrowing or blood flow effects. The new system is intended to add information about the plaque itself. Its two methods examine different characteristics of tissue while operating through the same catheter.
FLIm measures faint natural fluorescence from the artery wall. According to the researchers, that signal reflects aspects of the tissue’s biochemical composition. PS-OCT measures light scattered back from tissue to create a map of its microstructure. Used together, the techniques are designed to identify both structural and biochemical features of coronary plaque in real time.
That combination matters because plaque is not uniform. Plaque buildup can differ in composition and structure, and a detailed assessment could help clinicians better understand disease progression. The researchers say the system could ultimately support more personalized treatment, though that potential will require further clinical testing.
From laboratory prototype to clinical evaluation
Julien Bec, who directs engineering and regulatory work in the Marcu Lab, designed and built the catheter and its imaging console. Before the patient study, the device had been tested in animal models and samples of human coronary arteries. The completed 10-patient evaluation marks the next stage of that development path.
Laura Marcu, founding director of NCIBT and a professor of neurological surgery and biomedical engineering at UC Davis, described the study as a step toward improving how clinicians understand atherosclerotic cardiovascular disease. The group emphasizes that running a first-in-human study with an academic laboratory-developed catheter system is unusual, since such work is more commonly carried out by large medical-device companies.
That distinction also underscores the practical work behind a clinical imaging advance. A promising optical method must be packaged into a catheter small and flexible enough to navigate arteries, paired with a usable imaging console, and evaluated under regulatory oversight before it can be considered for broader clinical research.
Why plaque characterization is a major clinical goal
Cardiovascular disease remains the leading cause of death in the United States, according to the source material. Plaque accumulation in arteries can restrict blood flow and is associated with serious cardiovascular events. Better ways to characterize plaque could help researchers investigate how disease changes over time and how treatment affects the arterial wall.
The UC Davis team’s approach is not simply about producing a sharper image. It seeks to collect complementary information: microstructure from PS-OCT and biochemical signals from FLIm. If later studies show that these measurements can be interpreted reliably and linked to clinical decisions, clinicians may have a richer picture of coronary disease during catheter-based procedures.
For now, the completed study answers a more foundational question: whether the technology can be deployed in people under an investigational protocol. The report indicates that the answer was sufficient for the team to complete imaging in all 10 planned participants. It does not provide patient-level results, comparisons with existing imaging methods or evidence that treatment decisions changed because of the device.
What comes next
Further research will need to determine how consistently the dual-imaging system identifies meaningful plaque features, how its measurements compare with established tools, and whether using its information improves diagnosis or treatment planning. Studies will also need to examine how the technology performs across broader patient populations and clinical settings.
Those questions are central to translating a first-in-human feasibility effort into a clinical product. Atherosclerosis is a complex disease, and an imaging system’s value depends not only on the data it can acquire but also on whether clinicians can use that data to make better decisions for patients.
Still, the UC Davis study represents a notable milestone for intravascular optical imaging. By integrating two forms of information into a catheter system and completing an FDA-approved first-in-human evaluation, the researchers have created a platform for the next phase of clinical investigation into more detailed coronary plaque assessment.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
